Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.

Mierxiati AbudurexitiWenkai ZhuYuchen WangJun WangWenhao XuYongqiang HuangYao ZhuGuohai ShiHailiang ZhangYiping ZhuYijun ShenBo DaiFangning WanGuowen LinDingwei Ye

Published in: The Prostate (2020)

CPT1B is upregulated in prostate cancer and is correlated with poor prognosis, indicating its potential as a biomarker. AR inhibits the transcription of CPT1B. In the CRPC cell line, overexpression of CPT1B alone cannot promote enzalutamide resistance, but in the drug-resistant line C4-2R, overexpression of CPT1B can promote the resistance of C4-2R to enzalutamide.

Keyphrases

prostate cancer
drug resistant
poor prognosis
radical prostatectomy
multidrug resistant
long non coding rna
transcription factor
acinetobacter baumannii
cell proliferation